Lack of association of Aspergillus colonization with the development of bronchiolitis obliterans syndrome in lung transplant recipients: An international cohort study
Section snippets
Study design and patients
This was an international, multicenter, retrospective, non-interventional cohort study of patients who had received lung transplants. Fourteen lung transplant centers from around the globe participated, including the United States of America, Canada, France, Germany, Italy, The Netherlands, Spain, Switzerland, and Australia.
A total of 900 consecutive LTRs aged ≥18 years who underwent single lung, double lung, or heart–lung transplantation at the participating study centers from January 1, 2005
Demographics
A total of 900 LTRs were eligible for evaluation. We excluded 42 patients who received a prior lung transplant, 43 with missing BOS status, and 68 who died within 90 days of transplantation. As illustrated in Figure 1, 250 LTRs developed BOS within 4 years after transplantation, whereas 497 patients did not. Median follow-up time from lung transplantation to the end of their follow up was 3.7 years (IQR, 1.5–4.0 years). The characteristics of the cohort are described in Table 1. The mean age
Discussion
BOS is one of the leading causes of death beyond 1 year after transplant, affecting nearly half of recipients at 5 years after transplant, and 75% at 10 year after transplant.33, 34 Many factors have been reported to contribute toward BOS. However, the quality of data is often an issue, as almost all existing evidence derives from retrospective studies with no control groups and only reflects the experience of single centers. Additionally, the number of patients included were often small,
Disclosure statement
This study was funded by Pfizer. Pfizer did not have any input in the manuscript preparation and conclusion. Dr Shahid Husain has received research grants from Merck and Pfizer, educational grant from Astellas, and consultancy fees from Cidara. F.P.S. has received research support from Pfizer, Gilead, Shire, CSL Behring, Qiagen, Ansun Biopharma, and Whiscon. Drs Jay Aram and Muhammad Younus are employees of Pfizer Inc, New York, USA. L.G.S. has received research support from Gilead, and Pfizer,
References (66)
- et al.
Advances in understanding bronchiolitis obliterans after lung transplantation
Chest
(2016) - et al.
Observational study of lung transplant recipients surviving 20 years
Respir Med
(2016) - et al.
Registry of the International Society for Heart and Lung Transplantation: Twenty-third official adult lung and heart-lung transplantation report—2006
J Heart Lung Transplant
(2006) - et al.
Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria
J Heart Lung Transplant
(2002) - et al.
Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation
Chest
(1995) - et al.
Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation
J Thorac Cardiovasc Surg
(1997) - et al.
Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome
Am J Transplant
(2005) - et al.
Colonization with small conidia Aspergillus species is associated with bronchiolitis obliterans syndrome: a two-center validation study
Am J Transplant
(2013) - et al.
Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant
Am J Transplant
(2005) - et al.
Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis
Respir Med
(2009)
The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000
J Heart Lung Transplant
A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients
J Heart Lung Transplant
ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients
J Heart Lung Transplant
The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report—2010
J Heart Lung Transplant
Spirometrically significant acute rejection increases the risk for BOS and death after lung transplantation
Am J Transplant
Bronchiolitis obliterans syndrome: the final frontier for lung transplantation
Chest
Acute antibody-mediated rejection after lung transplantation
J Heart Lung Transplant
Risk factors for bronchiolitis obliterans: a systematic review of recent publications
J Heart Lung Transplant
Lung transplantation and gender effects on survival of recipients with cystic fibrosis
J Heart Lung Transplant
The impact of alemtuzumab and basiliximab induction on patient survival and time to bronchiolitis obliterans syndrome in double lung transplantation recipients
Am J Transplant
Effects of prophylactic use of sirolimus on bronchiolitis obliterans syndrome development in lung transplant recipients
Ann Thorac Surg
Pseudomonas aeruginosa induced airway epithelial injury drives fibroblast activation: a mechanism in chronic lung allograft dysfunction
Am J Transplant
Recipient HLA-DR3, tumour necrosis factor-alpha promoter allele-2 (tumour necrosis factor-2) and cytomegalovirus infection are interrelated risk factors for chronic rejection of liver grafts
J Hepatol
Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation
J Heart Lung Transplant Off Publ Int Soc Heart Transplant
Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial
J Heart Lung Transplant
Staphylococcus aureus infections in the early period after lung transplantation: epidemiology, risk factors, and outcomes
J Heart Lung Transplant
A new classification system for chronic lung allograft dysfunction
J Heart Lung Transplant
Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors
J Heart Lung Transplant
Prevalence and outcome of bronchiolitis obliterans syndrome after lung transplantation. Washington University Lung Transplant Group
Ann Thorac Surg
An international ISHLT/ATS/ERS clinical practice guideline: summary for clinicians. Bronchiolitis obliterans syndrome complicating lung transplantation
Ann Am Thorac Soc
An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome
Eur Respir J
The significance of a single episode of minimal acute rejection after lung transplantation
Transplantation
Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management
J Thorac Cardiovasc Surg. [discussion]
Cited by (10)
The lung microbiome in lung transplantation
2021, Journal of Heart and Lung TransplantationCitation Excerpt :Aspergillus is associated with early anastomotic complications, as it grows in ischemic anastomotic tissue.98 Several studies have linked Aspergillus infection or colonization to later CLAD,99,100 although recent work found no association.101 Invasive Candida infections are common after lung transplantation, usually involving bloodstream, pleural space, or surgical site.74,102
Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Case Report
2020, Transplantation ProceedingsCitation Excerpt :Further examination of our patient showed consistently only P aeruginosa colonization. There has been discussion about infectious causes that could contribute to the development of BOS in a population of lung transplant recipients; association with P aeruginosa, various respiratory viruses, and fungi including Aspergillus were reported but with conflicting results [6,7]. However, no such analysis was done in the setting of BOS in GvHD of HSCT recipients.
Fungal infection and chronic lung allograft dysfunction: A dangerous combination
2022, Transplant Infectious DiseaseFungal infections in lung transplantation
2021, Journal of Thoracic DiseaseChronic Lung Allograft Dysfunction: Evolving Concepts and Therapies
2021, Seminars in Respiratory and Critical Care Medicine